General
Preferred name
NARATRIPTAN
Synonyms
GR-85548A D3 ()
Naratriptan (D3 Hydrochloride) ()
Naratriptan HCl ()
Amerge ()
Naramig ()
GR-85548A hydrochloride ()
Naratriptan (hydrochloride) ()
NARATRIPTAN HYDROCHLORIDE ()
GR-85548A ()
GR 85548A ()
Naratriptan ()
P&D ID
PD009622
CAS
143388-64-1
121679-13-8
Tags
available
drug
Approved by
FDA
First approval
1998
Drug indication
Migraine
Headache
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 ¦ÌM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms[1][2][3][4].
PRICE 35
DESCRIPTION Marketed formulations may contain naratriptan hydrochloride (PubChem CID 60875). (GtoPdb)
PRICE 79
DESCRIPTION Naratriptan Hydrochloride is the hydrochloride salt form of naratriptan, a sulfonamide with selective serotonin (5-HT) 1 receptor agonistic activity and anti-migraine property. Naratriptan hydrochloride (GR-85548A hydrochloride) binds selectively and with high affinity to the 5-HT1D and 5-HT1B receptor subtypes. Activation of these 5-HT1D/B receptors located on intracranial blood vessels leads to vasoconstriction and provides relief of migraine headaches. Naratriptan hydrochloride may also exerts its effect by stimulation of 5-HT1D/1B receptors on sensory nerve endings in the trigeminal system thereby decreasing the release of pro-inflammatory neuropeptides. (TargetMol Bioactive Compound Library)
DESCRIPTION Naratriptan, a 5-HT1B/1D receptor agonist, could be used in the treatment of migraine. (BOC Sciences Bioactive Compounds)
DESCRIPTION Naratriptan is a selective agonist of 5-HT1 receptor and is is used for the treatment of migraine headaches. (TargetMol Bioactive Compound Library)
Compound Sets
29
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
87
Properties
(calculated by RDKit )
Molecular Weight
335.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
2.07
TPSA
65.2
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT1
HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Pathway
Neuronal Signaling
GPCR/G protein
Neuroscience
Indication
migraine headache
MOA
serotonin receptor agonist
Therapeutic Class
Vasoconstrictor Agents
Solubility
DMSO 74 mg/mL (198 mM)
Water 22 mg/mL (59 mM)
Source data